JLK

JLK EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of JLK (322510.KQ) as of Nov 4, 2026 is -15.64. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -14.97 — a change of 4.48% (lower).

EV/FCF

-15.64

YoY

4.48%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of JLK is 2025 -15.64 . EV/FCF (Enterprise Value to Free Cash Flow) of JLK was 2024 -14.97 . It decreases by 4.48% lower compared to the previous year.

The JLK EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-40.69 KRW
Jan 1, 2019
-23.04 KRW
Jan 1, 2020
-8.53 KRW
Jan 1, 2021
-25.33 KRW
Jan 1, 2022
-23.72 KRW
Jan 1, 2023
-29.98 KRW
Jan 1, 2024
-14.97 KRW
Jan 1, 2025
-15.64 KRW
The JLK EV/FCF history
YEAREV/FCFYoY
-15.64+4.48%
-14.97-50.08%
-29.98+26.41%
-23.72-6.37%
-25.33+196.99%
-8.53-62.98%
-23.04-43.37%
-40.69-5.32%
-42.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JLK Stock analysis

What does JLK do? JLK, Inc. generates revenue through AI medical analysis solutions, AI industry and security analysis solutions, and AI medical diagnostic platforms. The company's products include AI medical systems, AI quantitative analysis platforms, and AI remote platforms, which are sold to healthcare providers and medical institutions. The primary customer segments are hospitals and clinics seeking advanced diagnostic tools for brain disease detection. Revenue streams are derived from software licensing and subscription services for these AI-driven diagnostic systems. JLK, Inc. focuses on developing AI-based data-driven diagnostic systems specifically for brain disease detection. The company's AI medical diagnostic platforms are designed to provide accurate and efficient analysis for medical professionals. These platforms are part of the broader suite of AI medical analysis solutions that include AI quantitative analysis and AI remote platforms. The firm's target market includes healthcare facilities requiring cutting-edge technology for neurological diagnostics. The company's software products, such as AI medical systems and AI quantitative analysis platforms, are marketed to healthcare institutions for integration into their diagnostic workflows. Revenue is primarily generated through licensing agreements and recurring subscription fees for access to the AI-driven diagnostic tools. These solutions are positioned as essential for modern healthcare providers aiming to enhance diagnostic accuracy and patient outcomes in brain disease detection. JLK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JLK stock

EV/FCF (Enterprise Value to Free Cash Flow) of JLK is -15.64 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of JLK changed from -14.97 to -15.64, representing a 4.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) JLK since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s JLK with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — JLK

All Key Metrics — JLK